home.social

#obesitydrug — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #obesitydrug, aggregated by home.social.

  1. Denmark @[email protected] ·

    europesays.com/dk/76544/ Novo Nordisk slightly raises outlook as first-quarter profit beats forecast #EliLilly #NovoNordisk #ObesityDrug #OperatingProfit

    #operatingprofit #obesitydrug #novonordisk #elililly
  2. Denmark @[email protected] ·

    europesays.com/dk/56710/ Breakthrough in Weight Loss: Novo Nordisk’s High-Dose Wegovy #EliLilly #FDA #NovoNordisk #ObesityDrug #prescription #Telehealth #USPharmacies #Wegovy #Wegovy®HD #WeightLoss

    #weightloss #wegovy #uspharmacies #telehealth #prescription #obesitydrug
  3. Denmark @[email protected] ·

    europesays.com/dk/47846/ Lexicon earns $10M as Novo starts LX9851 Phase 1 #LexiconPharmaceuticals #LX9851 #LXRX #MetabolicDisorders #MilestonePayment #NovoNordisk #ObesityDrug #Phase1Study

    #phase1study #obesitydrug #novonordisk #milestonepayment #metabolicdisorders #lxrx
  4. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
    #YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #cagrisema #elililly #obesitydrug #clinicaltrialresults
  5. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
    #YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #cagrisema #elililly #obesitydrug #clinicaltrialresults
  6. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
    #YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  7. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
    #YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #cagrisema #elililly #obesitydrug #clinicaltrialresults
  8. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
    #YonhapInfomax #NovoNordisk #EliLilly #ObesityDrug #CagriSema #StockDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #elililly #obesitydrug #cagrisema #stockdrop
  9. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
    #YonhapInfomax #NovoNordisk #EliLilly #ObesityDrug #CagriSema #StockDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #elililly #obesitydrug #cagrisema #stockdrop
  10. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
    #YonhapInfomax #NovoNordisk #EliLilly #ObesityDrug #CagriSema #StockDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #elililly #obesitydrug #cagrisema #stockdrop
  11. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
    #YonhapInfomax #NovoNordisk #EliLilly #ObesityDrug #CagriSema #StockDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  12. Yonhap Infomax News @[email protected] ·

    Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.
    #YonhapInfomax #NovoNordisk #EliLilly #ObesityDrug #CagriSema #StockDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #novonordisk #elililly #obesitydrug #cagrisema #stockdrop
  13. Yonhap Infomax News @[email protected] ·

    US biotech firm Terns Pharmaceuticals sees potential 5-fold stock increase on promising obesity drug developments and analyst optimism
    #YonhapInfomax #TernsPharmaceuticals #ObesityDrug #GLP1 #StockForecast #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ternspharmaceuticals #obesitydrug #glp1 #stockforecast #biotechindustry